<DOC>
	<DOCNO>NCT00293254</DOCNO>
	<brief_summary>This study investigate safety efficacy raltegravir therapy Human Immunodeficiency Virus ( HIV ) -infected patient fail current therapy 3-class antiviral resistance .</brief_summary>
	<brief_title>A Study Evaluate Safety Efficacy Raltegravir ( MK0518 ) HIV-Infected Patients Failing Current Antiretroviral Therapies ( 0518-019 )</brief_title>
	<detailed_description>The primary double-blind study raltegravir versus placebo extend 156 week follow open-label raltegravir phase continue participant raltegravir placebo group receive open-label raltegravir additional 84 week maximum duration 240 week . Participants viral failure Week 16 may receive open-label raltegravir Week 240 .</detailed_description>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Raltegravir Potassium</mesh_term>
	<criteria>Patient must HIV positive HIV RNA value within range require study Patient must document failure certain antiretroviral therapy Patient must antiretroviral therapy least past two month Patient le 16 year old Additional study criterion discuss identify study doctor</criteria>
	<gender>All</gender>
	<minimum_age>16 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>Treatment Experienced</keyword>
</DOC>